99
Participants
Start Date
February 1, 2013
Primary Completion Date
August 17, 2016
Study Completion Date
August 17, 2016
Carboplatin
Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
Paclitaxel
Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
Bevacizumab
Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
Institut J Paoli I Calmettes; Chir II, Marseille
Centre Francois Baclesse; Chir Gynecologique, Caen
HOPITAL JEAN MINJOZ; Oncologie, Besançon
Hopital Rangueil; CHIR Generale Et Gynecologique, Toulouse
Institut Bergonie; Oncologie, Bordeaux
Centre Val Aurelle Paul Lamarque; Chir A1, Montpellier
Centre Oscar Lambret; Cancerologie Gynecologique, Lille
Centre Jean Perrin; Chir Generale Oncologie, Clermont-Ferrand
Institut Curie; Chir Generale Gyneco Oncologique, Paris
Hop Europeen Georges Pompidou; Gynecologie, Paris
HOPITAL TENON; Cancerologie Medicale, Paris
Chu D'Amiens, Amiens
Centre Rene Huguenin; Chir Generale Oncologique, Saint-Cloud
Institut Gustave Roussy; Departement Chirurgie Generale /Unite Tarn, Villejuif
Centre Antoine Lacassagne; Hopital De Jour A2, Nice
Hoffmann-La Roche
INDUSTRY